Development of LCN2 inhibitor for multiple sclerosis

K-MEDI hub

IMMUNOLOGY	Hit
Product Type	Small molecule
Indication	Multiple sclerosis
Target	Lipocalin-2 (LCN2)
MoA(Mechanism of Action)	Inhibition of immune cell infiltration by LCN2 inhibition
Competitiveness	1. Differentiated MOA : LCN2-LCN2R interaction inhibition 2. Potential to by-pass BTK-related adverse effects
Development Stage	Hit
Route of Administration	Oral

KDDF
Korea Drug Development Fund